CN101528732B - 用作cb1受体调节剂的1,5-二苯基-3-苄氨基-1,5-二氢吡咯烷-2-酮 - Google Patents

用作cb1受体调节剂的1,5-二苯基-3-苄氨基-1,5-二氢吡咯烷-2-酮 Download PDF

Info

Publication number
CN101528732B
CN101528732B CN2007800394497A CN200780039449A CN101528732B CN 101528732 B CN101528732 B CN 101528732B CN 2007800394497 A CN2007800394497 A CN 2007800394497A CN 200780039449 A CN200780039449 A CN 200780039449A CN 101528732 B CN101528732 B CN 101528732B
Authority
CN
China
Prior art keywords
phenyl
formula
compound
trifluoromethoxy
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800394497A
Other languages
English (en)
Chinese (zh)
Other versions
CN101528732A (zh
Inventor
D·S·科菲
J·胡
S·J·克丁
J·H·小克鲁欣斯基
J·M·肖斯
D·E·塔珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101528732A publication Critical patent/CN101528732A/zh
Application granted granted Critical
Publication of CN101528732B publication Critical patent/CN101528732B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800394497A 2006-10-23 2007-10-22 用作cb1受体调节剂的1,5-二苯基-3-苄氨基-1,5-二氢吡咯烷-2-酮 Expired - Fee Related CN101528732B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
US60/862,540 2006-10-23
PCT/US2007/082042 WO2008070306A2 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators

Publications (2)

Publication Number Publication Date
CN101528732A CN101528732A (zh) 2009-09-09
CN101528732B true CN101528732B (zh) 2013-04-03

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800394514A Expired - Fee Related CN101528733B (zh) 2006-10-23 2007-10-22 作为cbl’受体调节剂的1,5-二苯基-3-吡啶基氨基-1,5-二氢吡咯烷-2-酮
CN2007800394497A Expired - Fee Related CN101528732B (zh) 2006-10-23 2007-10-22 用作cb1受体调节剂的1,5-二苯基-3-苄氨基-1,5-二氢吡咯烷-2-酮

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2007800394514A Expired - Fee Related CN101528733B (zh) 2006-10-23 2007-10-22 作为cbl’受体调节剂的1,5-二苯基-3-吡啶基氨基-1,5-二氢吡咯烷-2-酮

Country Status (23)

Country Link
US (2) US7998985B2 (enExample)
EP (2) EP2099784B1 (enExample)
JP (2) JP5331001B2 (enExample)
KR (2) KR101088236B1 (enExample)
CN (2) CN101528733B (enExample)
AR (1) AR063497A1 (enExample)
AT (1) ATE492543T1 (enExample)
AU (1) AU2007329808B2 (enExample)
BR (1) BRPI0717347A2 (enExample)
CA (2) CA2667372C (enExample)
CL (1) CL2007003002A1 (enExample)
CY (1) CY1111140T1 (enExample)
DE (1) DE602007011495D1 (enExample)
DK (2) DK2094684T3 (enExample)
EA (2) EA015175B1 (enExample)
ES (2) ES2356025T3 (enExample)
MX (2) MX2009004053A (enExample)
PE (1) PE20080926A1 (enExample)
PL (2) PL2094684T3 (enExample)
PT (2) PT2099784E (enExample)
SI (2) SI2099784T1 (enExample)
TW (1) TW200825067A (enExample)
WO (2) WO2008070305A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
JP5539322B2 (ja) * 2008-04-22 2014-07-02 イーライ リリー アンド カンパニー Ｃｂ−１リガンドとしての１，５−ジフェニル−ピロリジン−２−オン化合物
MX2010011547A (es) * 2008-04-22 2010-11-09 Lilly Co Eli Compuestos de 1,5-difenil-pirrolidin-2-ona como ligandos de cb-1.
WO2010057000A2 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
CA2805091A1 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions comprising a homopathically potentized form of an antibody to human cannabinoid receptor
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
US20240158384A1 (en) * 2020-12-14 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
CA2553372A1 (en) 2004-02-19 2005-09-01 Solvay Pharmaceuticals B.V. Imidazoline derivatives having cb1-antagonistic activity
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds

Also Published As

Publication number Publication date
KR20090071613A (ko) 2009-07-01
SI2094684T1 (sl) 2011-04-29
EP2099784B1 (en) 2012-12-12
CA2667372C (en) 2013-09-03
PT2094684E (pt) 2011-01-28
JP5331001B2 (ja) 2013-10-30
EA200970405A1 (ru) 2009-12-30
BRPI0717347A2 (pt) 2014-01-14
DE602007011495D1 (de) 2011-02-03
EP2094684A2 (en) 2009-09-02
MX2009004054A (es) 2009-04-27
JP5331002B2 (ja) 2013-10-30
US20090275618A1 (en) 2009-11-05
TW200825067A (en) 2008-06-16
WO2008070305A2 (en) 2008-06-12
CY1111140T1 (el) 2015-06-11
WO2008070306A2 (en) 2008-06-12
AU2007329807A1 (en) 2008-06-12
DK2099784T3 (da) 2013-01-14
MX2009004053A (es) 2009-04-27
WO2008070305A3 (en) 2008-08-28
DK2094684T3 (da) 2011-03-14
CN101528733B (zh) 2013-10-16
ES2356025T3 (es) 2011-04-04
AR063497A1 (es) 2009-01-28
PE20080926A1 (es) 2008-07-19
JP2010507590A (ja) 2010-03-11
SI2099784T1 (sl) 2013-02-28
US7998985B2 (en) 2011-08-16
EA015745B1 (ru) 2011-10-31
US8168659B2 (en) 2012-05-01
EP2094684B1 (en) 2010-12-22
EA015175B1 (ru) 2011-06-30
KR101088236B1 (ko) 2011-11-30
CA2667210A1 (en) 2008-06-12
CN101528732A (zh) 2009-09-09
JP2010507589A (ja) 2010-03-11
EP2099784A2 (en) 2009-09-16
PL2099784T3 (pl) 2013-05-31
WO2008070306A3 (en) 2008-07-31
AU2007329808B2 (en) 2013-11-07
CL2007003002A1 (es) 2008-06-06
AU2007329808A1 (en) 2008-06-12
US20100016375A1 (en) 2010-01-21
CA2667372A1 (en) 2008-06-12
KR101088229B1 (ko) 2011-11-30
CA2667210C (en) 2013-09-24
ATE492543T1 (de) 2011-01-15
PL2094684T3 (pl) 2011-05-31
EA200970404A1 (ru) 2009-10-30
PT2099784E (pt) 2013-01-04
ES2398388T3 (es) 2013-03-15
KR20090069316A (ko) 2009-06-30
CN101528733A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
CN101528732B (zh) 用作cb1受体调节剂的1,5-二苯基-3-苄氨基-1,5-二氢吡咯烷-2-酮
CN101426783B (zh) 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的环己基吡唑-内酰胺衍生物
JP5395808B2 (ja) オレキシン受容体アンタゴニストとしてのヘテロアリール誘導体
CN1863770B (zh) 具有杂环取代基的环胺base-1抑制剂
CN100384836C (zh) 新型环状酰胺衍生物
EP3538525B1 (en) 3-substituted propionic acids as alpha v integrin inhibitors
CN106061968B (zh) 四唑酮-取代的二氢吡啶酮mgat2抑制剂
JP2007514690A (ja) ヒスタミンｈ３アンタゴニストとしてのベンズアゼピン誘導体
EP3538528A1 (en) Pyrrole amides as alpha v integrin inhibitors
CN105848483A (zh) RORγt 的喹啉基调节剂
WO2001074769A1 (en) Pharmaceutically active pyrrolidine derivatives as bax inhibitors
AU2001252222A1 (en) Pharmaceutically active pyrrolidine derivatives as bax inhibitors
CA2767770C (en) Pyrrolidine derivatives as nk3 receptor antagonists
AU2009238444B2 (en) 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
CN101460503A (zh) 新的mch受体拮抗剂
CN119816491A (zh) 新的螺环己烷衍生物，含有它们的药物组合物以及它们作为抗细胞凋亡抑制剂的用途
CN102007121A (zh) 作为cb-1配体的1，5-二苯基-吡咯烷-2-酮化合物
HK1160649A (en) Isoquinolinone derivatives as nk3 antagonists
ZA200102758B (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 Receptors (antipsychotic agents).

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130403

Termination date: 20141022

EXPY Termination of patent right or utility model